Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report

Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report

The combination of the immune-checkpoint inhibitor pembrolizumab plus lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, has been approved as standard second-line treatment for patients with recurrent or metastatic endometrial cancer progressed to first-line platinum-based chemotherapy rega...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Fabbri, Linda Galvani, Claudio Zamagni
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2025-06-01
Series:Drugs in Context
Subjects:
adverse events
antiangiogenic therapy
endometrial cancer
immunotherapy
progression-free survival
Online Access:https://www.drugsincontext.com/long-sustained-response-during-second-line-pembrolizumab-plus-lenvatinib-in-a-patient-with-recurrent-endometrial-carcinoma-a-case-report/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.drugsincontext.com/long-sustained-response-during-second-line-pembrolizumab-plus-lenvatinib-in-a-patient-with-recurrent-endometrial-carcinoma-a-case-report/

Similar Items